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Case Report
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A Case Report and Review of the Literature
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Abstract
Primary adenocarcinoma of the urethra is rarely reported. We report a case of a 47-year-old male with
symptoms of urinary obstruction started 2 years before diagnosis. Video-assisted urethrocystoscopy revealed a
papillary mass almost obstructing the entire lumen with bleeding. Pathology report was consistent with primary
adenocarcinoma of the urethra.
Introduction
Primary urethral carcinoma (UC) is defined as a tu-mor that is first detected in the urethra unlike secondary UC
that is a recurrence of tumor in the urethra after prior diagnosis
and treatment of carcinoma somewhere else in the urinary tract.
Most causes of secondary UCs are reported after radical cy-
stectomy of the urinary bladder caused by bladder cancer.1
Primary UC is considered a rare cancer,2–4 accounting for <1%
of allmalignancies3with an incidence rate of 4/1,000,000/year.2
The survival for superficial type is 83% and for deep type it is
36%.4 Most primary UCs are of transitional type and squamous
cell type, with less than 5% being reported as adenocarcinoma.5
Here we report a patient with symptomatic urinary obstruction
having a well-differentiated adenocarcinoma of the urethra.
Case Report
A 47-year-old male patient with 2-year history of symp-
tomatic urinary obstruction was presented to our urology clinic
at a tertiary referral hospital. He was also complaining of fre-
quent gross terminal hematuria and lower urinary tract symp-
toms. Six months ago, he had total hematuria, and upon
referring to a urologist, he was found to have urethral stric-
ture and a retrograde urethrography, after which video ure-
throcystoscopy was performed (Fig. 1). Urethroscopy revealed
mild penile urethral narrowing at the level of bulbar urethra,
which was dilated. It showed a papillary tumor with bleeding,
measuring 2 to 3 cm and almost filling the lumen. A sample was
taken and sent to a pathologist. The membranous, prostatic
urethra and bladder neck were intact as well as no pathology
was seen inside the bladder. The pathology report showed
papillary formed neoplastic tissue, in which atypical tall co-
lumnar epithelial with enlarged hyperchromatic nuclei and
prominent nucleoli was clear. Cytoplasm and the underlying
inflamed stroma infiltratedmostly by acute inflammatory cells,
consistent with well-differentiated adenocarcinoma with focal
mucin production (Fig. 2). The tumor had invaded into the
submucosa and the deep margin is free of tumor. A pelvic
MRI with and without contrast was performed to investigate
possible metastasis (Fig. 3). A 44· 19mm intraurethral en-
hancing circumferential mass in the bulbar portion of the urethra
was seen that causes expansion of urethra. The membranous
part of the urethra was clear. There was no evidence of extra-
corporal invasion of the mass. Prostate gland with 55 cc volume
was enlarged. The bladder had irregular border. The patient
underwent surgery and the mass was removed. After 6 months
of follow-up, the patient is fine and has no complaints.
Discussion
Tumors of the male urethra are categorized according to
location and histologic features.6 The UC is localized to the
bulbomembranous urethra in 60% of the patients, penile
urethra in 30% of patients, and prostatic urethra in 10% of
patients.7 A recent population-based study, Surveillance,
Epidemiology, and End Results (SEER), and analysis of
2065 men with primary UC (mean age: 73 years) showed
that urothelial carcinoma (78%) was most common, and
squamous cell carcinoma (SCC) (12%) and adenocarcinoma
(5%) were significantly less frequent.5
1Urology and Nephrology Research Center, Department of Urology and Renal Transplantation, Shahid Labbafinejad Medical Center,
Shahid Beheshti University of Medical Sciences, Tehran, Iran.
2Department of Medical Laboratory, Shahid Labbafinejad Medical Center, Iranian Social Security Organization Tehran, Iran.
3Division of Interventional Radiology, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts.
ª Abbas Basiri et al. 2015; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative
Commons License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly credited.
JOURNAL OF ENDOUROLOGY CASE REPORTS
Volume 1.1, 2015
Mary Ann Liebert, Inc.
Pp. 75–77
DOI: 10.1089/cren.2015.0026
75
For male primary UC, various predisposing factors have
been reported, including urethral strictures,2,4,8,9 chronic irri-
tation after intermittent catheterization or urethroplasty,10–12
external beam radiation therapy,13 radioactive seed implanta-
tion,14 chronic urethral inflammation urethritis after sexually
transmitted diseases (i.e., condylomata associated with human
papillomavirus 16),4,15,16 and congenital origin (i.e., clear cell
adenocarcinoma).17
The histologic subtype of UC also varies by anatomic loca-
tion. Carcinomas of the prostatic urethra are of transitional cell
origin in 90% and of squamous cell origin in 10%; and carci-
nomas of the bulbomembranous urethra are of squamous cell
origin in 80%, of transitional cell origin in 10%, and of ade-
nocarcinoma or undifferentiated in 10%.7 Male UC can spread
by direct extension to adjacent structures, usually involving the
vascular spaces of the corpus spongiosum and the periurethral
tissues, or it can metastasize through lymphatic embolization to
regional lymph nodes. The lymphatic vessels from the anterior
urethra drain into the superficial and deep inguinal lymph nodes
and occasionally into the external iliac lymph nodes. Tumors of
the posterior urethramost commonly spread to the pelvic lymph
nodes. Palpable inguinal lymph nodes occur in about 20% of
cases and almost always represent metastatic disease, in con-
trast to penile cancer, in which a large percentage of palpable
nodes may be inflammatory. Hematogenous dissemination is
uncommon except in advanced disease.18
When primary UC becomes clinically apparent, most pa-
tients (45%–57%) present with symptoms associated with lo-
cally advanced disease (T3/T4).19,20 At initial presentation,
visible hematuria or bloody urethral discharge is reported in as
much as 62% of the cases. Further symptoms of locally ad-
vanced disease include an extraurethral mass (52%), bladder
outlet obstruction (48%), pelvic pain (33%), urethrocutaneous
fistula (10%), abscess formation (5%), or dyspareunia.20
The onset of malignant change in a patient with chronic
urethral stricture disease may be insidious, and a high index of
clinical suspicion is necessary to diagnose these tumors expe-
diently. The most common presenting symptoms are urethral
bleeding, a palpable urethral mass, and obstructive voiding
symptoms.2 In men, physical examination should comprise
palpation of the external genitalia for suspicious indurations or
masses and a digital rectal examination.21 Bilateral inguinal
palpation should be conducted to assess the presence of en-
larged lymph nodes, describing location, size, and mobility.22
The role of urinary cytology in primary UC is limited, and
its sensitivity ranges between 55% and 59%.23 Detection rate
depends on the underlying histologic entity. In male patients,
the sensitivity for urothelial carcinoma and SCCwas reported
to be 80% and 50%, respectively.21
Depending on the depth of infiltration according to the
TNM classification for UC, superficial tumors as papillary
carcinoma in situ or at the basement membrane crossing are
FIG. 1. Video urethrocystoscopy showing papillary tumor
at the level of bulbar urethra.
FIG. 2. Papillary formed neoplastic tissue with atypical
tall columnar epithelial, enlarged hyperchromatic nuclei,
prominent nucleoli.
FIG. 3. Sagittal T2 weighted shows a high signal large well-
defined lesion at the bulbar portion of corpus spongiosum.
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described as T1. The infiltration of the corpus spongiosum,
prostate, or periurethral muscle is classified with T2. In ad-
dition, the involvement of the corpora cavernosa, the bladder
neck, or a prostate capsule sunburst as T3 and an infestation
of adjacent organs are defined as T4.2
The primary treatment is surgery. For UC in stage pT2,
there are two curative surgical approaches: in the proximal
urethra, this involves the prostatic urethra and membranous
urethra. Should a penectomy with prostatectomy be neces-
sary, it should be performed with cystoprostatectomy and
removal of the pelvic lymph nodes.2
Earlier lesions of the bulbomembranous urethra have been
treated effectively by transurethral resection or by segmental
excision of the involved urethral segment with an end-to-end
anastomosis. Unfortunately, cases appropriate for limited
resection are rare.7
A statement on evidence-based therapies is difficult. The
etiology may contribute to the development of a UC by
several factors.2 In a distal localization, the bulbar, penile
urethra, and navicular fossa comprising a penis-conserving
surgery can be performed.2
Adenocarcinoma of the urethra, although rare, should be in
deferential diagnosis of patients with a long history of urinary
obstruction and gross hematuria.
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